NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (OTCBB:PSTI) (DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of malignant, ischemic and autoimmune disorders, announced today that its previously disclosed two hundred for one reverse stock split has become effective. The Company’s name was also changed from Pluristem Life Systems, Inc. to Pluristem Therapeutics Inc. Pluristem’s shares are now trading on a reverse split-adjusted basis on the OTC Bulletin Board under the symbol "PSTI.OB", which replaces the previous symbol "PLRS.OB". The reverse stock split is made in relation to Pluristem’s application to list its shares on the NASDAQ Capital Market and to broaden the availability of its common stock to both institutional and individual investors.
